World Health Or­ga­ni­za­tion rec­og­nizes new an­ti­fun­gal class

BioSpectrum (Asia) - - Who News -

Scynexis, Inc., a biotech­nol­ogy com­pany de­liv­er­ing in­no­va­tive ther­a­pies for dif­fi­cult-to-treat and of­ten lifethreat­en­ing in­fec­tions, re­cently an­nounced that the

World Health Or­ga­ni­za­tion’s (WHO) In­ter­na­tional Non­pro­pri­etary Name (INN) group has as­signed the generic name “ibrex­a­fungerp” for its lead can­di­date SCY-078, the first rep­re­sen­ta­tive of a novel oral and in­tra­venous (IV) triter­penoid an­ti­fun­gal fam­ily.

Scynexis is de­vel­op­ing ibrex­a­fungerp for the treat­ment of mul­ti­ple se­ri­ous fun­gal in­fec­tions, in­clud­ing vul­vo­vagi­nal can­didi­a­sis (VVC), in­va­sive can­didi­a­sis (IC), in­va­sive as­pergillo­sis (IA) and re­frac­tory in­va­sive fun­gal in­fec­tions.

The INN sys­tem was es­tab­lished to fa­cil­i­tate the iden­ti­fi­ca­tion of phar­ma­ceu­ti­cal sub­stances or ac­tive phar­ma­ceu­ti­cal in­gre­di­ents in a unique, glob­ally-rec­og­nized man­ner. Ob­tain­ing a non-pro­pri­etary, or generic, name is a re­quired step in bring­ing a new drug to mar­ket. Generic names of phar­ma­co­log­i­cal­lyre­lated sub­stances demon­strate their re­la­tion­ship by us­ing a com­mon stem, al­low­ing med­i­cal prac­ti­tion­ers and phar­ma­cists to rec­og­nize sub­stances hav­ing sim­i­lar phar­ma­co­log­i­cal ac­tiv­ity. This is im­por­tant for the clear iden­ti­fi­ca­tion, safe pre­scrip­tion and dis­pens­ing of medicines to pa­tients.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.